BACKGROUND: In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy. AIM: To identify baseline and on-treatment factors associated with HBsAg loss at Week 72 and provide a model for predicting HBsAg loss in patients receiving combination therapy for 48 weeks. METHODS: A secondary analysis of data from an open-label study where patients were randomised to TDF (300 mg/day, oral) plus PEG-IFN (PI, 180 μg/week, subcutaneous) for 48 weeks (TDF/PI-48w); TDF plus PEG-IFN for 16 weeks, TDF for 32 weeks (TDF/PI-16w+TDF-32w); TDF for 120 weeks (TDF-120w) or PEG-IFN for 48 weeks (PI-48w). Logistic regression methods were used to identify models that best predicted HBsAg loss at Week 72. RESULTS:Rates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09). The only baseline factor associated with response was genotype A. HBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001). HBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72. CONCLUSIONS:HBsAg decline at Week 24 of TDF plusPEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.
RCT Entities:
BACKGROUND: In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy. AIM: To identify baseline and on-treatment factors associated with HBsAg loss at Week 72 and provide a model for predicting HBsAg loss in patients receiving combination therapy for 48 weeks. METHODS: A secondary analysis of data from an open-label study where patients were randomised to TDF (300 mg/day, oral) plus PEG-IFN (PI, 180 μg/week, subcutaneous) for 48 weeks (TDF/PI-48w); TDF plus PEG-IFN for 16 weeks, TDF for 32 weeks (TDF/PI-16w+TDF-32w); TDF for 120 weeks (TDF-120w) or PEG-IFN for 48 weeks (PI-48w). Logistic regression methods were used to identify models that best predicted HBsAg loss at Week 72. RESULTS: Rates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09). The only baseline factor associated with response was genotype A. HBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001). HBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72. CONCLUSIONS: HBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.
Authors: Carla S Coffin; Scott K Fung; Fernando Alvarez; Curtis L Cooper; Karen E Doucette; Claire Fournier; Erin Kelly; Hin Hin Ko; Mang M Ma; Steven R Martin; Carla Osiowy; Alnoor Ramji; Edward Tam; Jean Pierre Villeneuve Journal: Can Liver J Date: 2018-12-25
Authors: Jonathan Liu; Pedro Goicochea; Timothy Block; Carol L Brosgart; Eric F Donaldson; Oliver Lenz; Seng Gee Lim; Ed G Marins; Poonam Mishra; Marion G Peters; Veronica Miller Journal: J Virus Erad Date: 2017-01-01
Authors: Sang Hoon Ahn; Patrick Marcellin; Xiaoli Ma; Florin A Caruntu; Won Young Tak; Magdy Elkhashab; Wan-Long Chuang; Fehmi Tabak; Rajiv Mehta; Jörg Petersen; William Guyer; Belinda Jump; Alain Chan; Mani Subramanian; Gerald Crans; Scott Fung; Maria Buti; Giovanni B Gaeta; Aric J Hui; George Papatheodoridis; Robert Flisiak; Henry L Y Chan Journal: Dig Dis Sci Date: 2018-08-22 Impact factor: 3.199
Authors: Teresa Broquetas; Montserrat Garcia-Retortillo; Juan José Hernandez; Marc Puigvehí; Nuria Cañete; Susana Coll; Beatriz Cabrero; Maria Dolors Giménez; Ricard Solà; José A Carrión Journal: PLoS One Date: 2017-11-30 Impact factor: 3.240
Authors: Dae Won Jun; Sang Bong Ahn; Tae Yeob Kim; Joo Hyun Sohn; Sang Gyune Kim; Se Whan Lee; Byung Ho Kim; Dong Joon Kim; Ja Kyung Kim; Hyoung Su Kim; Seong Gyu Hwang; Won Choong Choi; Won Young Tak; Heon Ju Lee; Ki Tae Yoon; Byung Cheol Yun; Sung Wook Lee; Soon Koo Baik; Seung Ha Park; Ji Won Park; Sol Ji Park; Ji Sung Lee Journal: Chin Med J (Engl) Date: 2018-07-20 Impact factor: 2.628
Authors: Anna S Lok; Fabien Zoulim; Geoffrey Dusheiko; Henry L Y Chan; Maria Buti; Marc G Ghany; Anuj Gaggar; Jenny C Yang; George Wu; John F Flaherty; G Mani Subramanian; Stephen Locarnini; Patrick Marcellin Journal: Hepatol Commun Date: 2019-10-10